At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 320 enrolled
Drug / intervention
Ustekinumab +1 moredrug
Likely dose
Ustekinumab 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis
In Brief
A Phase 2 clinical trial evaluating Ustekinumab and Placebo for Psoriasis. Completed, enrolled 320 participants.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2003
Primary CompletionJun 2004
Study CompletionMar 2005
First PostedMay 2006
TodayJul 2026
First PostedMay 3, 2006
Enrollment StartNov 1, 2003
Primary CompletionJun 1, 2004
Study CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 20.2 years ago
Interventions
Ustekinumabdrug
Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
Placebodrug
Patients in the placebo group will receive placebo medication.